Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009

IA Binswanger, PJ Blatchford, SR Mueller… - Annals of internal …, 2013 - acpjournals.org
Chinese translation Background: Among former prisoners, a high rate of death has been
documented in the early postrelease period, particularly from drug-related causes. Little is …

Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial

JS Kutner, PJ Blatchford, DH Taylor… - JAMA internal …, 2015 - jamanetwork.com
Importance For patients with limited prognosis, some medication risks may outweigh the
benefits, particularly when benefits take years to accrue; statins are one example. Data are …

High‐dose monthly vitamin D for prevention of acute respiratory infection in older long‐term care residents: a randomized clinical trial

AA Ginde, P Blatchford, K Breese… - Journal of the …, 2017 - Wiley Online Library
Objectives To determine the efficacy and safety of high‐dose vitamin D supplementation for
prevention of acute respiratory infection ( ARI ) in older long‐term care residents. Design …

Risk factors for all-cause, overdose and early deaths after release from prison in Washington state

IA Binswanger, PJ Blatchford, RG Lindsay… - Drug and alcohol …, 2011 - Elsevier
BACKGROUND: High mortality rates after release from prison have been well-documented,
particularly from overdose. However, little is known about the risk factors for death after …

Clinical risk factors for death after release from prison in Washington State: A nested case–control study

…, SR Mueller, TP Baggett, PJ Blatchford - …, 2016 - Wiley Online Library
Background and aims While mortality rates after prison release are high, little is known
about clinical risk factors for death. We sought to identify risk and protective factors for all‐cause …

A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma

…, J Arcaroli, MA Rudek, A Dasari, PJ Blatchford… - Investigational new …, 2014 - Springer
Purpose The notch pathway is overexpressed in pancreatic adenocarcinoma. RO4929097,
an oral inhibitor of the γ-secretase enzyme has been safely given as a single agent in …

Decline in endothelial function across the menopause transition in healthy women is related to decreased estradiol and increased oxidative stress

KL Moreau, KL Hildreth, J Klawitter, P Blatchford… - Geroscience, 2020 - Springer
Endothelial function declines progressively across stages of the menopause transition;
however, the mechanisms contributing to this decline are unknown. We hypothesized that …

Oral iloprost improves endobronchial dysplasia in former smokers

RL Keith, PJ Blatchford, J Kittelson, JD Minna… - Cancer prevention …, 2011 - AACR
There are no established chemopreventive agents for lung cancer, the leading cause of
cancer death in the United States. Prostacyclin levels are low in lung cancer and …

Final report of a phase I trial of olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer

SD Karam, K Reddy, PJ Blatchford, T Waxweiler… - Clinical Cancer …, 2018 - AACR
Purpose: Our goal was to evaluate the safety and toxicity of combining a PARP inhibitor,
olaparib, with cetuximab and fractionated intensity-modulated radiotherapy for patients with …

Long-term follow-up of desmoid fibromatosis treated with PF-03084014, an oral gamma secretase inhibitor

…, B Huang, JT Schowinsky, PJ Blatchford… - Annals of Surgical …, 2018 - Springer
Background Desmoid fibromatosis is a fibroblastic neoplasm driven by aberrations within
the WNT pathway, exhibiting mutations in β-catenin or APC. We review the long-term follow-up …